In the longest controlled trial of a GHRH(1-29) analog in older adults, 16 weeks of nightly dosing raised IGF-1 within 2 weeks and increased lean body mass in men, but produced no significant change in fat mass. Body composition results take longer than most before-and-after content implies.
Sermorelin does not produce a visible transformation in weeks. The measurable changes arrive in a fixed order: IGF-1 rises within 2 weeks [1], sleep depth improves within the first month, and body composition shifts over 3 to 6 months when dosing and sleep are consistent. Understanding that order is the difference between a protocol you evaluate correctly and one you abandon at week 6 because the mirror has not changed.
- IGF-1 is measurable within 2 weeks and is the only objective early marker of response [1]
- Sleep quality is the first subjective change most patients report, typically at 2 to 4 weeks
- In a 16-week controlled trial, lean body mass increased in men only, and fat mass did not change significantly [1]
- Visceral fat reduction in GHRH-analog studies required roughly 6 months of treatment [2]
- Six months is the minimum honest evaluation window. Photos at 30 days show nothing clinically meaningful
What the Trial Data Actually Shows
The most directly relevant controlled data on sermorelin-class therapy in older adults comes from a randomized placebo-controlled study of [[Nle27]GHRH(1-29)NH2, a norleucine-substituted analog of the same fragment sermorelin is built on, at 10 mcg/kg subcutaneously each night for 16 weeks in men and women aged 55 to 71](https://pubmed.ncbi.nlm.nih.gov/9141536/) [1]. The outcomes are worth reading precisely, because they are more specific and more modest than most marketing suggests.
| Outcome measured | Result at 16 weeks |
|---|---|
| Serum IGF-1 | [Increased within 2 weeks in both sexes, sustained throughout](https://pubmed.ncbi.nlm.nih.gov/9141536/) [1] |
| Nocturnal GH | [Increased in both men and women](https://pubmed.ncbi.nlm.nih.gov/9141536/) [1] |
| Lean body mass | [Increased in men](https://pubmed.ncbi.nlm.nih.gov/9141536/) [1] |
| Fat mass | No significant change over the 16-week period [1] |
| Skin thickness | [Increased in both men and women](https://pubmed.ncbi.nlm.nih.gov/9141536/) [1] |
Two points follow. First, the biochemical response is fast and reliable, which is why the 90-day IGF-1 retest is the correct checkpoint rather than a scale or a photograph. Second, fat loss is not the early signal. A patient judging sermorelin on visible fat change at 16 weeks would conclude it failed, while their labs showed a clear axis response.
Realistic Before-and-After Timeline
The sequence below follows from the mechanism. Sermorelin is a GHRH analog that stimulates the pituitary to release its own GH, and the downstream effects accumulate through IGF-1 rather than appearing acutely.
| Period | What typically changes | How to verify it |
|---|---|---|
| Weeks 1 to 2 | IGF-1 begins rising [1]. Nothing visible | Serum IGF-1 draw |
| Weeks 2 to 4 | Deeper sleep, fewer night wakings, easier mornings | Sleep tracker, written log |
| Weeks 4 to 12 | Recovery between training sessions improves. Early lean-mass response in men [1] | 90-day IGF-1 retest, training performance |
| Months 3 to 6 | Body composition shifts. Waist is more sensitive than scale weight | DEXA or waist tape under identical conditions |
| Month 6 and beyond | Visceral and abdominal fat reduction becomes measurable in GHRH-analog data [2] | DEXA, repeat IGF-1 |
Six months is the minimum period over which a sermorelin protocol can be fairly judged. Stopping at 8 to 12 weeks because nothing is visible discards the protocol before its primary endpoint.
Why Sleep Changes First
The majority of daily GH release occurs during slow-wave sleep [3], which is why bedtime dosing on an empty stomach is a clinical requirement rather than a convenience. Patients who dose correctly usually notice sleep depth before anything else, because the intervention acts directly on the pulse that governs the rest of the axis. Patients who inject after a late meal blunt that pulse through somatostatin feedback and often report no change at all.
Body Composition: What to Expect and When
GHRH-analog therapy acts on visceral and abdominal fat more than on total scale weight. In pooled human studies of GHRH analogs, 6 months of treatment produced significant visceral adipose tissue reduction relative to placebo [2]. That is the honest timeframe. It also explains why the scale is a poor instrument here: adding lean mass while losing fat can leave weight unchanged as body composition improves.
- Waist circumference at the navel, same time each morning, is more informative than scale weight
- DEXA at baseline and at 6 months is the most reliable way to document real change
- Lean mass response is more consistently documented in men than in women [1]
- Results depend on training and protein intake. Sermorelin does not build tissue without a stimulus
What Sermorelin Does Not Change
Credibility on this topic requires stating the limits plainly. Sermorelin restores GH axis signaling. It is not a weight loss drug, and it does not produce the rapid soft-tissue changes associated with supraphysiologic exogenous HGH.
- It does not replace a caloric deficit for patients seeking significant weight loss
- It will not produce results when the pituitary cannot respond to GHRH stimulation
- It does not correct untreated hypothyroidism, which independently blunts the GH response
- Skin changes are gradual. The controlled data supports increased skin thickness, not a cosmetic transformation [1]
How to Document Your Own Before and After
Most published before-and-after images are uncontrolled for lighting, posture, hydration, and time of day, which makes them useless as evidence. A protocol you can actually evaluate uses the same measurements taken under the same conditions.
- Draw a baseline IGF-1 before the first dose. Without it the 90-day retest has no reference point
- Record waist circumference at the navel, first thing in the morning, before eating
- Book a DEXA scan at baseline if the budget allows, and repeat it at 6 months
- Log sleep with one consistent method for the first 4 weeks
- Repeat IGF-1 at 90 days and review it against the age-adjusted reference range with your prescribing physician
A 90-day IGF-1 that has not moved points to a dosing, timing, or absorption problem, or to a pituitary that is not responding. It is a signal to reassess the protocol with your physician, not to raise the dose on your own.
Frequently Asked Questions
How long before you see results from sermorelin?
IGF-1 rises within about 2 weeks of correct nightly dosing [1], and sleep improvement is usually reported between weeks 2 and 4. Visible body composition change takes considerably longer. In GHRH-analog studies, meaningful visceral fat reduction required roughly 6 months [2]. A 16-week controlled trial of [Nle27]GHRH(1-29)NH2, a close analog of the fragment sermorelin is based on, found increased lean body mass in men but no significant change in fat mass over that period [1].
Are sermorelin before and after photos reliable?
Generally no. Photos are uncontrolled for lighting, posture, hydration, and time of day, and the changes sermorelin produces over 3 to 6 months are gradual rather than dramatic. Objective markers are far more useful: a baseline and 90-day IGF-1, waist circumference measured under identical conditions, and DEXA at baseline and 6 months.
What results did clinical trials of sermorelin actually show?
The most relevant controlled data used [Nle27]GHRH(1-29)NH2, a norleucine-substituted analog of the fragment sermorelin is based on, at 10 mcg/kg subcutaneously nightly for 16 weeks in adults aged 55 to 71. It found IGF-1 elevation within 2 weeks in both sexes and sustained throughout, increased nocturnal GH, increased skin thickness in both sexes, and increased lean body mass in men [1]. Fat mass did not change significantly over that window. The only adverse effect reported was a transient hyperlipidemia that resolved.
Why did I see no change after 3 months on sermorelin?
Check three things before concluding it failed. First, dosing timing: sermorelin must be taken at bedtime on an empty stomach, because elevated glucose blunts the GH pulse through somatostatin feedback. Second, your 90-day IGF-1: if it rose, the protocol is working and the timeline for visible change is simply longer than 3 months. Third, thyroid status, since untreated hypothyroidism suppresses the GH response independently.
Does sermorelin change your face or skin?
The controlled trial data supports a measurable increase in skin thickness in both men and women after 16 weeks of a nightly GHRH(1-29) analog [1]. That is a real finding, but it describes a tissue property rather than a cosmetic transformation. Claims of dramatic facial change within weeks are not supported by the published evidence.
Do men and women see different results from sermorelin?
The available trial data suggests they do. In the 16-week [Nle27]GHRH(1-29)NH2 study, lean body mass and insulin sensitivity gains reached significance in men, while IGF-1, nocturnal GH, and skin thickness increased in both sexes [1]. Estrogen status affects IGF-1 response, which is one reason protocols for women are evaluated differently.
References
- Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women Journal of Clinical Endocrinology & Metabolism, 1997. PMID: 9141536. https://pubmed.ncbi.nlm.nih.gov/9141536/
- Effects of growth hormone-releasing hormone on visceral fat, metabolic and cardiovascular indices in human studies Growth Hormone and IGF Research, 2015. PMC4324360. https://pmc.ncbi.nlm.nih.gov/articles/PMC4324360/
- Growth hormone secretion during sleep Journal of Clinical Investigation, 1968. PMID: 5675428. https://pubmed.ncbi.nlm.nih.gov/5675428/
